ANIX Anixa Biosciences: ערך חשבונאי למניה

The market trend for Anixa Biosciences, Inc. (ANIX) shares reflects the company's dynamics, where success depends on the uniqueness of FDA patents and the quality of clinical trials in the oncovaccine sector. The business model relies on developing CAR-T therapy for patients with severe pathologies, with the current metric standing at 0.42. Future commercialization of these developments will ensure monopoly status and the pricing power to independently set high treatment costs.

For an investor in Anixa Biosciences, Inc. (ANIX), which focuses on precision onco-immunology and CAR-T therapy, the balance between R&D potential and tangible assets is key. This indicator calculates the net asset value per share, determining the stock's real asset foundation using the Graham method. Analyzing the historical book value per share chart allows for an assessment of the asset's margin of safety without ignoring the scaling prospects of biopharmaceutical innovations.